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Background: Today the impairment of metabolism and obesity are being extensively investigated due to the
significant increase of the prevalence of these diseases. There is scientific evidence that probiotics are beneficial for
human health. Thus, the aim of the study was to investigate the effect of multiprobiotic “Symbiter acidophilic
concentrated” on obesity parameters in the rats under experimental obesity.
Methods: The study was carried out on 60 newborn Wistar rats, divided into 3 groups, 20 animals in each
(females – n = 10, males – n = 10): intact rats, monosodium glutamate (MSG-) and MSG + probiotic group. Rats of
intact group were administered with saline (8 μl/g, subcutaneously (s.c.)). Newborns rats of MSG-group and MSG +
probiotic group were injected with a solution of MSG (4.0 mg/g) s.c. at 2nd – 10th postnatal days. The MSG + probiotic
group was treated with 140 mg/kg (1.4 × 1010 CFU/kg) of multiprobiotic “Symbiter”. MSG-group was treated with
2.5 ml/kg of water (per os) respectively. Administration was started at the age of 4 weeks just after wean and continued
for 3 month intermittently alternating two-week course of introduction with two-week course of break.
Results: Neonatal treatment with MSG caused a stunted growth in both MSG-groups, which manifested with significantly
smaller naso-anal length compared to adult intact rats. There was no significant difference in weight between intact and
MSG-groups on 120th day. The adiponectin level in the serum of rats with MSG-induced obesity decreased by 2.43 times
(p = 0.001) in males and 1.75 (p = 0.020) in females. Concentration of leptin in adipose tissue were significantly higher
by 45.9% (p = 0.019) and 61.2% (p = 0.009) respectively in males and females compared to intact rats. Our study has
indicated that daily oral administration of multiprobiotic to neonatal MSG-treated rats by 2-week courses led to
significant reduce of total body and VAT weight with subsequent improvement in insulin sensitivity and
prevention of non-alcoholic fatty liver (NAFLD) development.
Conclusions: These results have shown that periodic treatment with multiprobiotic prevents the MSG-induced
obesity and NAFLD development.
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Obesity has dramatically increased during the past decades
and has now reached epidemic proportions in both devel-
oped and developing countries [1,2]. It is a heterogeneous
disorder which has been associated with an increased risk
of many serious illnesses such as cardiovascular diseases
[3], hypertension [4], dyslipidemia [4], diabetes mellitus
[5] and some types of cancer including colon cancer [6],
lung cancer [7], breast cancer [8], uterine [9] and ovarian
cancer [10]. As of 2008, The World Health Organization
claimed that 1.5 billion adults, in the age of 20 and older,
were overweight. Among them over 200 million of men
and nearly 300 million of women were obese [11]. The
rate of obesity also increases with age, at least up to 50 or
60 years old [12].
Most of medications for treatment of obesity are taken
out the production because of their adverse effects. Orli-
stat is the only drug that could be taken by patients for
the prolonged time. However, little attention is paid to
the search of means for obesity prophylaxis. In current
scientific literature there are a lot of studies that confirm
beneficial effects of probiotics on human organism. The
question about probiotics impact on fat metabolism and
obesity is being actively debated in the scientific literature.
The gut microbiota has been recently proposed to be an
environmental factor involved in the control of body
weight and energy homeostasis [13-17]. This “exteriorized
organ” contributes to human homeostasis via multiple
metabolic functions and diverse control mechanisms.
In several studies it was revealed the positive effects of
probiotics use under the conditions of experimental
obesity [18,19]. In our previous work we have shown that
probiotics mixture of lyophilized strains Lactobacillus
casei IMVB-7280, Bifidobacterium animalis VKL and
Bifidobacterium animalis VKB at least partially prevent
the MSG-induced obesity in rats [20]. But studies have
shown that multistrain probiotics are more effective
than monostrain probiotics [21]. Also it is interesting to
compare the influence of the lyophilized and alive strains
on the obesity and reveal the gender-specific differences
in the obesity development. Given the above the aim of
our work was to investigate the prophylactic influence of
short periodical courses of the alive multiprobiotic admin-
istration on the obesity and non-alcoholic fatty liver devel-
opment (NAFLD) development induced by the neonatal
MSG treatment in 4-month male and female rats.
Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health
and the general ethical principles of animal experiments,
approved by the First National Congress on BioethicsUkraine (September 2001). The protocol was approved
by the Committee on the Ethics of Animal Experiments
of the Taras Shevchenko National University of Kyiv
(Protocol number: 18/2013). The rats were kept in col-
lective cages in controlled conditions of temperature
(22 ± 3°C), light (12 h light/dark cycle) and relative
humidity (60 ± 5%). The animals were fed laboratory chow
(PurinaW) and tap water ad libitum.
Study design
We included 60 newborn Wistar rats, divided to 3 groups
of 20 animals each. All groups were equally represented
by both sexes (females – n = 10, males – n = 10). Newborns
rats of intact group were administered with saline sub-
cutaneously (s.c.) in the volume of 8 μl/g at 2nd, 4th, 6th,
8th and 10th postnatal days. Newborns rats of MSG-group
and MSG + probiotic group received a solution of MSG
(4.0 mg/g of body weight) s.c. at 2nd, 4th, 6th, 8th and 10th
postnatal days [22]. Within 4 months after birth rats were
on a normal diet. MSG+ probiotic group received multipro-
biotic “Symbiter” in dose 140 mg/kg (1.4 × 1010 CFU/kg)
at volume 2.5 ml/kg per os (p.o.). Multiprobiotic contains
concentrated biomass of 14 probiotic bacteria of genera
Bifidobacterium, Lactobacillus, Lactococcus, Propionibacter-
ium. MSG-group respectively received 2.5 ml/kg of water
(p.o.). Administration was started at the age of 4 weeks just
after wean and continued for 3 month intermittently alter-
nating two-week course of introduction with two-week
course of break.
Anthropometric measurements and obesity parameter
assessment
During 4 months in all groups the changes of body
weight and food intake were analyzed. In adult age, rats
from three experimental groups (n = 60) were weighed and
killed by cervical dislocation under urethane anesthesia.
We dissected and weighed visceral adipose tissue (VAT)
(epididymal, perirenal and omental fat).
For each animal at month 4 of life (120 days) we de-
termined existence of obesity using Lee index. It was
calculated as follow: the cube root of body weight (g)/
nasoanal length (cm). Rats presenting values higher than
0.300 were classified as obese, equal to or less than 0.300
as normal [23].
Sample collection and blood biochemistry analysis
Rats of all groups were fasted for approximately 12 hours
prior sacrifice. Rats were sacrificed by cervical dislocation
under urethane anesthesia. Blood was drawn from the
apex of the cardiac ventricle and few blood drops were
collected into a microcentrifuge tube containing a mixture
of NaF and EDTA in a 2:1 (w/w) ratio. For blood glucose
determination we used Trinder glucose oxidase method
on this aliquot of blood. The remaining blood sample was
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(2260 g) for 15 minutes. After centrifugation serum
supernatant for further analysis was aliquoted into
microcentrifuge tubes and stored at -80°C. Serum insu-
lin was determined using the Rat/Mouse Insulin ELISA
Kit (Linco Research, USA). The HOMA-IR was calcu-
lated as the product of multiplying of fasting blood
glucose and serum insulin divided by 22.5 [24]. ELISA
was used for determination of serum adiponectin and
leptin level and the VAT leptin by commercial kits
«BioVendor» (Czech Republic). The VAT for measur-
ing leptin was promptly harvested and immediately
flash-frozen in liquid nitrogen and stored at -80°C.
After defrosting the adipose tissue was homogenized with
TES-buffer (pH = 7.4, 10 mM of tris(hydroxymethyl)ami-
nomethane, 1 mM of EDTA, 250 mM of saccharose,
inhibitors of protease (2,5 μg/ml of leupeptin, 2,5 μg/ml
of aprotinin, 1 mM phenylmethanesulfonyl fluoride), 1%
Triton X-100) (1:4). At next step the homogenate was
centrifuged at 14000 rpm for 15 min under +4°C. The
bottom layer of the supernatant was harvested for the
leptin measuring.
Liver histology assessment
For histological analysis liver tissue samples from both
the right and left hepatic lobes were taken (sample size
0.5 × 0.5 cm). After fixed for 24 hours in a liquid Buena,
fragments of liver were dehydrated in alcohols of in-
creasing concentrations (from 70 ° to 96 °), embedded in
paraffin and then cut with a thickness of 5-6 microns
and stained with hematoxylin-eosin. A pathologist blinded
to group distributions performed the histological analyses
of slides using light microscopy («Olympus», Japan). To
assess morphological changes in liver we used NAS
(NAFLD activity score), which includes histological
features and has been defined as unweighted sum of
scores for steatosis (0-3), lobular inflammation (0-3)
and ballooning (0-2). Acording to NAS scores ≥5 are
diagnosed as non-alcoholic steatohepatitis (NASH), and
cases with a NAS <3 are mentioned as not NASH [25].
Statistical analysis
Statistical analysis performed by using SPSS-20 software.
All data in this study were expressed as means ± standard
deviation (M± SD) or %. Data distribution was analyzed
using the Kolmogorov-Smirnov normality test. Continu-
ous variables with parametric distribution were then
analyzed using Analysis of Variance (ANOVA) and if
the results were significant, a Fisher’s LSD Post Hoc test
was performed. For data with non-parametric distribution
Kruskall-Wallis test was used. Estimation of gender spe-
cific changes performed using Student’s t test for unpaired
values. For comparisons of categorical variables we con-
ducted χ2 test. The difference between groups was definedto be statistically significant when a p-value was less than
0.05.
Results
Impact of probiotic short-term courses on body weight
and obesity parameters
Figure 1 shows sex specific weight gain from 30 to
120 days of age in all experimental rats groups. In female
rats on day 30, 60 and 90 we observed significant higher
body weight in MSG- group comparative to intact control.
But on day 120 the weight did no differ between intact
and MSG- groups (p = 0.914). Short-term periodic admin-
istration of probiotic beginning from 30 days age lead to
weight reduction by 17.3% (p = 0.001) at 120 days age in
MSG-probiotic female rats comparative to MSG-group
(Figure 1A). Also the body weight in this group were sig-
nificantly lower by 14.3% (p = 0.001) comparative to intact
rats (Figure 1A).
Unlike female, in male rats on 30 days age we didn’t
find significant changes in body weight at all experimental
groups. Beginning from day 60 we established significant
weight gain in MSG-group comparative to other groups
and at day 120 the average rats body mass were 263.4 ±
26.9 g. Specifically, that additional diet correction with
multiprobiotic “Symbiter” led to weight reduction by
14.5% (p = 0.005) compared to the value seen in MSG-rats
after 3 month of feeding (Figure 1B).
Neonatal treatment with MSG caused a stunted growth
in both MSG-groups, which manifested with significant
smaller naso-anal length compared to intact rats. That’s
why in spite of lower weight in both sexes, after probiotic
administration, we stated development of obesity in 50% of
female and 40% of male animals from MSG-probiotic
group compared to intact rats which was totally confirmed
by Lee index higher than 0.300 (Figure 2A, B). On the other
hand, short-term periodic consumption of multiprobiotic
had a preventive effect on glutamate-induced obesity. Es-
pecially we observed significantly lower Lee index after
probiotic correction in females (0.301 ± 0.01 vs 0.313 ±
0.01, p = 0.024) and males (0.299 ± 0.007 vs 0.319 ± 0.01,
p = 0.004) compared to MSG-group (Figure 2A,B). The
incidence of obesity was also higher in MSG-group – in
females (90% vs 50%, p = 0,051) and respectively in
males (90% vs 40%, p = 0,019).
We observed 5-7 times increasing of total weight of
VAT in rats with MSG-group compared to intact con-
trol (Figure 3A,B). Gender specific analysis showed
the development of more pronounced visceral obes-
ity in males, because of significant higher deposition
of VAT in MSG-rats (18.72 ± 5.46 g vs 14.1 ± 2.89 g;
p = 0.036).
Short-term concomitant administration of probiotic bac-
teria led to a decrease of VAT weight by 52.43% (p = 0.001)
in females and respectively by 58.86% (p = 0.001) versus
Figure 1 Body weight changes in rats from birth to 4-month age (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05
compared to intact rats, # - p < 0.05 compared to MSG-group.
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the control values.
Due to establish the alteration of eating behavior
under conditions of MSG-induced obesity we examined
food intake in one-, two-, three- and four-month rats of all
group. It was shown the slight age-dependent increase in
food intake both in male and female rats. We have to notice
there was no any significant difference in food consumption
between experimental group that suggest MSG-obesity is
not a result of excessive caloric intake but associated with
the metabolic disorder (Figure 4А, B ).
Probiotic short-term courses improved insulin sensitivity
in obese-induced rats
The fasting blood glucose of MSG-rats were signifi-
cant higher compared to intact animals in both sexes(6.11 ± 1.15 vs 4.62 ± 0.42 mmol/L, p = 0.003 – in females;
6.17 ± 0.64 vs 4.59 ± 0.67 mmol/L, p = 0.001 – respectively
in males). Female rats from MSG-probiotic group pre-
sented significant decrease of fasting glucose level by
17.34% (p = 0.024) and males – by 16.04% (p = 0.010)
compared to MSG-group (Figure 5 A,B).
Analysis of the HOMA-IR and serum insulin concentra-
tions showed that under condition of MSG-induced obes-
ity rats became insulin resistant. Both the HOMA-IR
index (2.3 ± 1.2 vs 0.46 ± 0.21, p = 0.001 – in females;
2.77 ± 0.92 vs 0.66 ± 0.34, p = 0.001 – in males) and
serum insulin concentration (8.19 ± 2.90 vs 2.33 ± 1.16,
p = 0.001 – in females; 10.02 ± 2.62 vs 3.21 ± 1.53, p =
0.001 – in males) were significant higher in rats with
MSG-induced obesity compared to control (Figures 6A,B;
7A,B). As we mentioned above the 2-week periodic
Figure 2 Index Lee in4-month rats (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05 compared to intact rats, # - p < 0.05
compared to MSG-group.
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sensitivity which manifested with significant 2-fold de-
crease of HOMA-IR and fasting insulinemia in relation
to MSG-group. After treatment with probiotic the
HOMA-IR index did not exceed the normal range, but
was not significantly higher compared to intact control
rats (Figure 7A, B).
Impact of short-term probiotic courses on adipocytokine
levels in obese-induced rats
Analysis of the secretory function of adipose tissue showed
a change in concentration adipose-derived hormones
in rats with experimental obesity. Thus, the level of
adiponectin in the serum of rats with MSG-inducedobesity decreased by 2.43 times (p = 0.001) in males
and 1.75 (p = 0.020) in females (Figure 8 A,B). Concen-
tration of leptin in adipose tissue were higher by 45.9%
(p = 0.019) and 61.2% (p = 0.009) respectively in males
and females in comparison with intact control group
(Figure 9A,B). In serum leptin level was lesser than in the
VAT. MSG increased the leptin level by 93.3% (p < 0.05)
and 83.6% (p < 0.01) respectively both in males and females
(Figure 10 A,B). Gender specific analysis did not confirmed
changes of leptin concentrations in adipose tissue but all
experimental groups represented significantly lower serum
adiponectin concentrations in males compared to fe-
males (intact – 4.29 ± 1.67 vs 6.5 ± 1.99 μg/ml, p = 0.001;
MSG – 1.73 ± 0.56 vs 3.77 ± 1.64 μg/ml, p = 0.030).
Figure 3 Visceral adipose tissue weight in4-month rats (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05 compared to
intact rats, # - p < 0.05 compared to MSG-group.
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after probiotic administration in males by 89% (p = 0.028)
compared to MSG-group (Figure 8B) and females by
38.2% (p = 0.039) compared to MSG-group (Figure 8A).
The VAT leptin in males decreased by 14.3% (p = 0.047)
compared to MSG-group (Figure 9B) and in females – by
14.9% (p = 0.044) compared to MSG-group (Figure 9A).
The serum leptin in MSG-probiotic group decreased
insignificantly (Figure 10 A,B). Also showed that the
concentration of adiponectin and leptin in the case of
probiotics ration did not differ from the level of intact
rats (Figures 7A,B; 8A,B).
Thus, intermittent administration of probiotics for
two weeks courses restored the hormonal activity of
adipose tissue.Morphological changes in rat liver under the conditions
of obesity and probiotic administration
We found significantly lower total score (0.95 ± 0.15 vs
3.3 ± 0.28, p < 0.001), degree of steatosis (0.85 ± 0.13 vs
2.15 ± 0.16, p < 0.001) and manifestation of lobular inflam-
mation (0.1 ± 0.06 vs 0.95 ± 0.15, p < 0.001) due to NAFLD
activity score in MSG-probiotic group compared to
MSG-obesity (Table 1).
Discussion
A lot of factors lead to development of obesity. The most
important factors contributing to fat accumulation are
widespread net of fast food restaurants, which offer the
variety of energy-dense foods and low physical activity and
the genetic inheritance. Also It was shown contributing of
Figure 4 Dynamics of food intake changes in rats from 1-month to 4-month age (M ± SD, n = 10 in each group): A –females, B – males.
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among people with higher adiposity, sleep debt, endocrine
disruptors, pharmaceutical iatrogenesis, reduction in vari-
ability of ambient temperatures and intrauterine effects to
the obesity [26,27]. In general obesity develops when the
body receives more energy with food than it can spend.
Not the least role in increased energy consumption plays
monosodium glutamate (C5H8NO4Na, MSG, E621) which
is food additive and is found especially in fast food.
MSG can be formed naturally in various foods (cheese,
meat, etc.) [28]. Also it is largely used in the food indus-
try because it improves the taste of food and even can
mask the bad taste of stale products. That is why its
consumption steadily increases worldwide. In 1968, a re-
port appeared in the New England Journal of Medicine,
describing a complex of symptoms in patients who dined
in Chinese restaurants. The symptoms of the so-called
«Chinese restaurant syndrome» included numbness,
radiating to the back, arms, and neck; weakness; andpalpitations [29]. Cross-sectional and longitudinal studies
in healthy Chinese subjects showed correlation of MSG
intake with an increased risk of being overweight
irrespective of the total calorie intake and physical
activity [30,31].
Animal models support a causative association between
obesity and neonatal or maternal administration of high
doses of MSG [32]. MSG acts on immature neurological
mechanisms that regulate food intake and energy ex-
penditure by ablating cells in the arcuate nucleus of the
hypothalamus and destroying circumventricular neurons.
MSG altered the production of orexigenic and anorexi-
genic molecules as proopiomelanocortin, cocaine- and
amphetamine-regulated transcript and neuropeptide Y
[33]. Neonatal neurotoxity effect of MSG leading to the
development of neurochemical, endocrine, metabolic and
behavioural abnormalities in adulthood including hypo-
phagia, obesity, hypoactivity, delayed puberty, and elevated
plasma corticosterone levels [34]. Furthermore, stunted
Figure 5 Glucose level in serum of 4-month rats (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05 compared to intact
rats, # - p < 0.05 compared to MSG-group.
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increase in plasma triglycerides [35], insulin [36] and
fasting glucose levels [37] have been noted in rats.
Most of medications for treatment of obesity are taken
out the production because of their adverse effects. Orlistat
is the only drug that could be taken by patients for the
prolonged time. However, little attention is paid to the
search of means for prophylaxis of obesity. In current
scientific literature there are a lot of studies that con-
firm beneficial effects of probiotics on human organism.
The question about probiotics impact on fat metabolism
and obesity is being actively debated in the scientific litera-
ture. The gut microbiota has been recently proposed to be
an environmental factor involved in the control of bodyweight and energy homeostasis [13-17]. This “exteriorized
organ” contributes to our homeostasis via multiple
metabolic functions and diverse control mechanisms.
For example it involved in the extraction of calories
from ingested dietary substances, and it helps to store
these calories in host adipose tissue for later use. Pioneers
in study of the gut microbiota role for the development of
obesity and fat mass storage were Gordon et al. They de-
termined that parallel with lower energy intake young
conventionally reared mice had higher on 42% and 47%
total body fat and gonadal fat mass respectively as com-
pared with germ-free mice [25]. Authors firstly declared
that microbiota itself can increase energy yield from diet
of the host organism’s. Colonization within two weeks of
Figure 6 Insulin level in serum of 4-month rats (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05 compared to intact rats,
# - p < 0.05 compared to MSG-group.
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tionally reared mice is associated with increased insulin
resistance and provokes a 60% increase in total body fat
mass despite lower energy intake [13]. This fat mass
gain was even more pronounced when the gut microbial
community was derived from genetically obese (ob/ob)
mice [17].
Gut microbiota may change with body weight. Ley
et al. [27] recently analysed 5,088 bacterial 16S rRNA
gene sequences from the distal intestinal (cecal) microbiota
of genetically obese ob/ob mice, lean ob/+and wild-
type siblings, and their ob/+mothers, all fed the same
polysaccharide-rich diet. They demonstrated that com-
pared with lean mice obese animals have a 50% reductionin the abundance of Bacteroidetes and a proportional
increase in Firmicutes. Feeding of a high-fat/high-poly-
saccharide diet to genetically wild-type rodents led to
similar microbial changes [16]. Methanogenic Archaea
also located in ob/ob mice, which lead to increasing of
the efficiency of bacterial fermentation [29].
Similar to these animal experiments, Ley et al. demon-
strated that the ratio of Firmicutes/Bacteroidetes in the
distal gut microbiota is also increase in obese people
by comparison with lean people [38]. This proportion
increases with weight loss on a fat-restricted or
carbohydrate-restricted diet. Another study, without limit
of dietary components, described that Prevotellaceae, a
subgroup of Bacteroidetes, are significantly enriched in
Figure 7 HOMA-IR of 4-month rats (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05 compared to intact rats, # - p < 0.05
compared to MSG-group.
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lean and obese individuals [39]. The differences in micro-
bial composition between two studies were explained by
an increased capacity of the obesity-associated micro-
biome to harvest energy from the diet.
Controversial data were recently reported by Schwiertz
and colleagues [40]. They determined lower ratios of
Firmicutes to Bacterodetes in overweight human adults
compared to lean controls. Another study, using weight
loss diets, found no proof of the link between the proportion
of Bacteroidetes and Firmicutes and human obesity [41].
Kalliomaki et al. [42] examined if early differences in gut
microbiota composition in children can guide weight
development throughout early childhood. Overweightand obese children (n = 25) were selected. Early fecal
microbiota composition was analyzed by fluorescent in
situ hybridization (FISH) with additional flow cytometry.
They find that bifidobacterial numbers in fecal samples
during infancy were higher in children remaining normal
weight than in children becoming overweight, [2.19 × 109
[1.10–5.28] cells/g vs 1.20 × 109 [0.48–1.59] cells/g;
p = 0.02]. Overweight was also associated with a greater
number of Staphylococcus aureus. Author suggested that
changes in early life gut microbiota composition may be
associated with an increased risk of developing obesity in
later life.
These data suggest an association between obesity and
the intestinal microbiota. In several studies it was revealed
Figure 8 Adiponectin level in serum of 4-month rats (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05 compared to
intact rats, # - p < 0.05 compared to MSG-group.
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of experimental obesity [18,19]. In our previous work we
have shown that probiotics mixture of lyophilized strains
Lactobacillus casei IMVB-7280, Bifidobacterium animalis
VKL and Bifidobacterium animalis VKB at least partially
prevent the MSG-induced obesity in rats [20]. But studies
have shown that multistrain probiotics are more effective
than monostrain probiotics [21]. Also it is interesting to
compare the influence of the lyophilized and alive strains
on the obesity and reveal the gender-specific differences
in the obesity development. Given the above the aim of
our work was to investigate the prophylactic influence of
short periodical courses of the alive multiprobiotic admin-
istration on the obesity development induced by the neo-
natal MSG treatment in 4-month male and female rats.Thus, finding new non-toxic means of prevention and
treatment of obesity is one of the major problems of
modern science. Our study showed that short-term
periodic administration of multiprobiotic beginning from
childhood prevented development of MSG-induced obes-
ity in adult rats. This was confirmed by significant lower
incidence of obesity and mean value for Lee index and
reduction of total body and VAT weight in rats after
correction with multiprobiotic “Symbiter” compared to
MSG-group.
The most frequent cause which leads to the obesity
development is a dysbalance between energy intake and
energy expenditure. In this complex process genetic suscep-
tibility, environmental and lifestyle factors are involved. Re-
cent advances in next generation sequencing technology
Figure 9 Leptin level in adipose tissue of 4-month rats (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05 compared to
intact rats, # - p < 0.05 compared to MSG-group.
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the gut microbiota as an environmental factor that increase
energy yield from diet, regulate metabolism, integrate
peripheral and central food intake regulatory signals
and thereby increase body weight. Underlying mechanisms
whereby the gut microbiota contributes to host metabolism
were revealed from studies on germ-free mice which were
protected against developing diet-induced obesity.
One of the key mechanism by which germ-free animals
seem protected from diet-induced obesity is elevated
levels of fasting-induced adipose factor (FIAF), also known
as angiopoietin-like protein 4. FIAF is a circulating lipopro-
tein lipase (Lpl) inhibitor produced by the intestine, liver
and adipose tissue [43]. Conventionalization of germ-freemice suppresses expression of Fiaf in gut epithelial cells
[13]. Thereby lead to higher adipocyte Lpl activity results
in increased cellular uptake of fatty acids, adipocyte trigly-
ceride accumulation and greater fat storage. Germ-free
Fiaf–/– mice are similarly obese to their conventionally
reared counterparts. After conventionalization germ-free
Fiaf–/–mice produced higher on 57% total body fat as ob-
served in wild-type littermates [13]. Consistently, germ-
free Fiaf–/– mice fed by high-fat, high-carbohydrate diet
were not protected from diet-induced obesity, suggesting
that FIAF is a mediator of microbial regulation of energy
storage [44].
In contrast, mice fed by high-fat diet complemented with
Lactobacillus paracasei exhibited significantly reduced body
Figure 10 Leptin level in serum of 4-month rats (M ± SD, n = 10 in each group): A –females, B – males. * - p < 0.05, p < 0.01 compared to
intact rats.
Table 1 Morphological changes in rats liver assessed by NAFLD activity score (NAS)
Intact group (n = 20) MSG-obesity (n = 20) MSG-probiotic (n = 20)
Steatosis (0-3) 0.10 ± 0.1a 2.15 ± 0.16b 0.85 ± 0.13c
Lobular inflammation (0-2) 0.0 ± 0.0a 0.95 ± 0.15b 0.1 ± 0.06a
Ballooning degeneration (0–2) 0.0 ± 0.0a 0.15 ± 0.08a 0.0 ± 0.0a
Total NAS (0–8) 0.10 ± 0.1a 3.3 ± 0.28b 0.95 ± 0.15c
Data are presented as the M ± SEM. One-way ANOVA with post hoc comparisons by Fisher LSD test were performed for data analysis. a, b, c: shows significant
differences in the same row (p < 0.05).
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FIAF [45]. Fleissner et al. showed that germ-free mice on
high-fat diet showed increased intestinal mRNA expression
of Fiaf with no major changes in circulating FIAF compared
with conventionalised mice, suggesting that FIAF mechan-
ism is not universally associated with gut microbiota-
related fat mass development [46].
Furthermore, Backhed and colleagues have also dem-
onstrated that germ-free mice have increased levels of
phosphorylated AMP-activated protein kinase (AMPK) in
muscle and liver. AMPK is a key enzyme that controls
cellular energy status which activates key enzymes of
mitochondrial fatty acid oxidation, including acetyl-CoA
carboxylase (ACC) and carnitine-palmitoyltransferase I
(CTP1), indicative of increased energy expenditure. The
exact pathway whereby the microbiota signals to liver or
skeletal muscle AMPK is unclear but appears to be inde-
pendent from FIAF [44].
Another mechanism is related to energy extraction from
undigested food components. The gut microbiota that
digest complex dietary carbohydrates produces many
monosaccharides and short-chain fatty acids (SCFAs)
such as acetate, propionate, and butyrate [44] which rep-
resent an important energy source. Conventionalization of
germ-free mice doubled the density of small intestinal villi
capillaries [47] and enhanced uptake of this components
from the gut into the portal blood and eventually partici-
pate in hepatic de novo lipogenesis promoting fat accu-
mulation in the liver and adipose tissue [44]. This reaction
controlled by carbohydrate responsive element binding
protein (ChREBP) and sterol responsive element binding
protein (SREBP-1) [48]. We observed that multiprobiotic
administration from childhood lead to histological features
improvement which manifested with hepatic steatosis
attenuation and decreased lobular inflammation in MSG-
probiotic group. NASH we confirmed only in 20% of rats
with MSG-obesity (p = 0.035).
SCFAs act in the gut as signaling molecules and are
specific ligands for at least two G protein-coupled recep-
tors, GPR41 and GPR43, mainly expressed by intestinal
epithelial cells [49,50]. Samuel et al. have demonstrated
that conventionally raised Gpr41–/– mice and germ-free
Gpr41–/– mice colonized with only Bacteroides thetaiotao-
micron and Methanobrevibacter smithii are significantly
leaner than wild-type littermates, while there are no differ-
ences between wild-type or Gpr41–/– germ-free mice [51].
Gpr41, which is produced by enteroendocrine cells, might
be a regulator of host energy balance through effects that
are dependent upon the gut microbiota. Activation of
GPR41 increases production of peptide YY (PYY), an
enteroendocrine cell hormone that normally inhibits
gut motility, increases intestinal transit rate and reduces
extraction of energy from the diet, thus affecting peripheral
glucose utilisation [51]. Recent study has shown thatGpr43–/– mice are resistant to diet-induced obesity and
insulin resistance, at least partly due to Gpr43-regulated
energy expenditure [52].
Some lines of experimental evidence suggest that high-
fat diets may affect epithelial integrity due to changes in
the distribution and localisation of Zonula Occludens-1
(ZO-1) and Occludin (two tight junction proteins) in
intestinal tissue and hence lead to impaired gut perme-
ability, and consequently to low-grade systemic inflam-
mation [53-55]. Cani et al. demonstrated that bacterial
lipopolysaccharide (LPS), which continuously produced in
the gut through lysis of gram-negative bacteria is a
microbiota-related factor which can trigger the inflamma-
tory process by binding to the CD14 toll-like receptor-4
(TLR-4) complex at the surface of innate immune cells
[55]. Author mentioned that after 4 weeks of high-fat
feeding, mice exhibited an obese phenotype accompanied
by a change in gut microbiota composition (the reduction
of Bifidobacteria and Eubacteria spp.) and a two- to three-
fold increase in circulating LPS levels, which they called
“metabolic endotoxemia” since LPS plasma concentrations
were much lower than those observed during septic shock
[56]. In fact, in this study, continuous subcutaneous
low-rate infusion of LPS led to excessive weight gain
and insulin resistance in mice. Moreover, LPS receptor
Cd14-/- mice tend to be resistant to this chronic inflam-
matory state and were hypersensitive to insulin even
when they were fed a normal diet, suggesting that CD14
may modulate insulin sensitivity in physiological conditions
[57]. Deletion of TLR-4 prevented the high-fat diet–in-
duced insulin resistance [58].
They also demonstrated that modulation of gut micro-
biota, e.g. by antibiotic treatment or dietary intervention
with oligofructoses, reduced metabolic endotoxemia and
the cecal content of LPS, improved glucose intolerance,
insulin sensitivity and decreased body weight gain in
both high-fat fed and ob/ob mice [59,60].
In models of diabetes, probiotic intervention has been
examined for its ability to impact on metabolic biomarkers
of disease. Tabuchi et al showed that Lactobacillus rhamno-
sus GG improved glucose tolerance in the streptozotocin-
induced rat model of diabetes possibly due to prevention of
a decrease in insulin secretion [61]. Studies using the
traditional Indian yoghurt – dahi supplemented with
probiotic strains of Lactobacillus acidophilus and L.
casei have shown that this product can improve markers
of diabetes, including hyperglycemia, hyperinsulinemia in
high-fructose induced rat models of diabetes [62,63].
We first studied influence of probiotic administration
for insulin sensitivity in rat model of MSG-induced obesity.
Nagata et al. found that mice after neonatal treatment with
MSG were observed to be obese but had no polyphagia,
and were glycosuric by 29 weeks of age. The pathological
study showed hypertrophy of the pancreatic islet, with
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29 and 54 weeks aged compared to control mice [32].
From the other hand in the early phase of obesity level of
plasma glucose can be normal but associated with hyper-
insulinemia [64] which indicates that insulin resistance is
present and high insulin levels may be compensatory due
to direct hypersecretion of β cells [65].
Our data is agreed with recently reported studies [62,63]
and showed that in addition to reduction in total body
weight administration of multiprobiotic by short courses
led to improvement of insulin sensitivity that was con-
firmed by significant decreasing of hyperinsulinemia
and HOMA-IR in MSG-probiotic group compared to
MSG-animals. From the other hand we observed sig-
nificant increase of serum adiponectin, which define as
one of the main regulators of peripheral tissues sensitivity
to insulin [66], only in females compared to MSG-group.
As previously reported for MSG rats and mice, leptin
mRNA expression levels and serum levels in MSG-treated
mice were significantly higher compared to that in normal
controls [67,68]. The increased leptin production in
adipose tissues due to pancreatic hypertrophy and hyperin-
sulinaemia have been reported to induce the development
of leptin resistance [69]. We mentioned that probiotics
helped to restore the hormonal activity of adipose tissue.
Thus, concentration of leptin under the probiotics admis-
tration did not differ from the level of intact rats.Conclusion
In summary, we studied effectiveness of short-term periodic
consumption of multiprobiotic from childhood on meta-
bolic profile in adult rats with MSG-induced model of
obesity. Subcutaneous neonatal injection of MSG is able
to induce obesity without hyperphagia, which diagnosed
by high Lee index and characterized by small corporal
weight and naso-anal length. Obesity in rats caused by
alterations in hypothalamic arcuate nucleus and impairs
leptin and insulin signaling in this region resulting in
hyperleptinemia and hyperinsulinemia.
Our study has indicated that daily oral administration
of 2.5 ml/kg of alive multiprobiotic “Symbiter” containing
concentrated biomass of 14 probiotic bacteria of Bifidobac-
terium, Lactobacillus, Lactococcus, Propionibacterium gen-
era to neonatal MSG-treated rats by 2-weeks courses led to
significant reduce of total body and VAT weight, together
with improvement in insulin sensitivity and prevention of
NAFLD development.
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